Use of AEDs in 2011 and beyond:
optimizing clinical management
               December 3, 2011
          David M. Treiman, M.D.
              Director, Epilepsy Center,
          Newsome Chair in Epileptology,
           Barrow Neurological Institute;
   Professor of Bioengineering and Neuroscience,
              Arizona State University;
          Clinical Professor of Neurology,
     University of Arizona College of Medicine;
               Professor of Neurology,
      Creighton University School of Medicine
    American Epilepsy Society | Annual Meeting
       Learning Objectives
   Strategies for optimal use of AEDs in the
             treatment of epilepsy.
 Some thoughts on how AED use will evolve in
                the 21th century.
         American Epilepsy Society | Annual Meeting
               Guiding principle
          We obtain our data from
          population statistics; we treat
          individual patients.
Treiman
 AEDs are the mainstay
of epilepsy management.
 (2011: 14 1st-line AEDs in US)
Shhhh, Zog! . . . Here
comes one now!
         Strategies for use of AEDs
  be sure of the diagnosis, etiology, classification
   & seizure type(s)
  match AED to sz type & patient characteristics
  monotherapy if possible; polytherapy if
   necessary
  push to maximum tolerated dose
  change timing of dosing to reduce toxicity
  use pharmacokinetic principles to fine tune dose
  adjust for drug-drug interactions
  dont give up
Treiman Neuropsychiat Dis Treat 6:297308, 2010.
                               Diagnosis
             When in doubt, check it out!
     Does patient have epilepsy? Differentiate
          epileptic seizures
          syncope
          psychogenic events (15 - 30 % of referrals to
           epilepsy centers (Clin Neurol Neurosurg 111:1-9, 2009))
     Identify the seizure type(s)
     Choose AED by:
          Efficacy for control of specific seizure type
          Toxicity
              side effects profile
              modified by individual patient considerations
Treiman Neuropsychiat Dis Treat 6:297308, 2010.
            Effect of accurate Dx & Rx
              25 pharmaco-resistant patients
    25 patients referred for poor sz. control
         11 M, 14F; 19 LRE, 6 PGE  all followed for  1 year
    Outcome:
         17 (68%) > 50% reduction of sz frequency; 7 (28%) sz free;
            6 (24%) no change; 2 (8%) worse.
   SUCCESSFUL STRATEGIES:
                                         All patients     Responders
      in sz dx.                          14/25 (56%)      13/17 (76 %
      of AED                             19/25 (74%)      15/17 (88%)
      of AED dose                         6/25 (24%)       2/17 (12%)
Norton & Treiman, Epilepsia 28(5):582-3), 1987
      Seizure type and AED choice
 All current AEDs except ethosuximide are
  effective against partial onset seizures.
 Individual studies may favor one drug, but
  there is no consistent evidence for superiority
  of one drug over another.
 Five are broad spectrum, and effective against
  both partial onset and primarily generalized
  seizures:
     valproate
     lamotrigine
     topiramate
     zonisamide
     levetiracetam
                      Wilby et al. Health Technol Assess. 9:1157, 2005.
           Importance of Accurate Dx.
              Exacerbation of szs
      Drug          Seizure type(s) exacerbated
      _____________________________________
      CBZ, OXC      absence, myoclonic
      GPN, PGB      myoclonic
      LTG           myoclonic
      TIA, VGB      absence
Panayiotopoulos Clinical Guide to Epileptic Syndromes & their Rx., 2nd ed., 2010
True, Mr. Bascomb, thats not listed as one of the side effects.
                        Choice of AEDs
                    Individualize to patients
   ADVERSE REACTIONS                                     AED(s)
     hirsuitism, gum hyperplasia                         PHT
     alopecia, tremor                                    VPA
     weight gain                                         VPA, GBP, PGB
     weight loss                                         TPM, FBM, ZNS
     hyponatremia                                        CBZ, OXC
     teratogenicity                                      VPA
     cognitive impairment                                TPM
   COMPLIANCE ISSUES
     qd dosing possible                                  PHT, PB,TPM, ZNS
                                                         extended rel. AEDs
Modified from Treiman Neuropsychiat Dis Treat 6:297308, 2010.
  Example: VPA & wt. gain
Heavier children at greater risk
 Novak et al. (J Child Neurol 14:490-5, 1999)
    55 Children 1.8-16.9 y.o.
    Increase in weight Z-score and BMI significantly
     correlated with initial weight Z-score and BMI.
 Wirrell (Ped Neurol 28:236-9, 2003)
    72 children 10-17 y.o.
    Overweight or potentially overweight at onset predicted
     overweight at end.
    Higher BMI at initiation of VPA tended to have greater
     increase in BMI at end.
                           Monotherapy
     Variable percent (10  50%) get better sz
      control with polyRx; return to monoRx may
      improve seizure control.
     Easier to manage balance between efficacy
      and toxicity.
     No potential drug-drug interactions.
     May be more cost effective.
     Improved compliance and more convenient.
     ARs in monoRx half as frequent as w/ polyRx
Treiman Neuropsychiat Dis Treat 6:297308, 2010.
                     Adding a 2nd AED
     Existing AED should be in mid-therapeutic range.
     Add new AED using smallest pill (tablet or
      capsule) appropriate to patient.
     Start with one pill h.s.
     Increase daily dose by one pill each week, spacing
      as indicated.
     Monitor ARs and sz control by phone during
      titration.
     Re-evaluate when low maintenance dose is reached
     Adjust dose as indicated.
     Slowly withdraw first AED.
Treiman Neuropsychiat Dis Treat 6:297308, 2010.
             Management philosophy
      Why add 2nd AED before stopping 1st AED?
     Risk of increased seizures >> risk of new
      dose-related ARs.
     Important principle in patient management:
      Make only one change at a time, so you
      know what the effect of that change is.
Treiman Neuropsychiat Dis Treat 6:297308, 2010.
  Start low
  Go slow
Push the dose
                                 Reason to push dose:
                          Response is proportional to dose
                               (e.g. levetiracetam RCCT responder rate)
                                     50% Reduction in Weekly Seizure Frequency
                          40
                          35
                                                                             39.5
          % of Patients
                          30
                                                               35.2
                          25
                          20                    28.6
                          15
                          10
                           5        9.4
                           0
                                   Placebo      LEV           LEV           LEV
                                             1000 mg/day   2000 mg/day   3000 mg/day
Pooled data of responding patients by
randomized dose. Data on file. UCB Pharma Inc.
          Push dose
Push the dose sufficiently to either
 achieve seizure control or produce
 dose-related side effects, using the
 therapeutic range as a guide.
However, do not be inhibited by the
 therapeutic range which is only a
 statistical probability statement that
 has been determined empirically.
  Therapeutic ranges of common AEDs
        Drug                  Total concentration   Usual adult dose
                                     g/mL               mg/day
    carbamazepine                     4-12              800-2400
    ethosuximide                     40-100             750-1000
    gabapentin                        4-16             1800-3600
    lacosamide                                          200-400
    lamotrigine                      2-20               300-500
    levetiracetam                   20-60              1000-3000
    oxcarbazepine                   10-15              1200-3600
    phenobarbital                   15-45               180-240
    phenytoin                        8-25               300-400
    pregabalin                                          150-600
    tiagabine                        5-70                16-64
    topiramate                       2-25               200-600
    valproate                       50-150             1000-3000
    zonisamide                      10-40               100-400
Modified from Treiman, 1995
I owe my reputation to the fact
that I use digitalis in doses the
text books say are dangerous
and in cases the text books
say are unsuitable.
   - Karel Frederick Wenckebach
    (1844 - 1940)
                      Caveats
1. Drugs that can be rapidly titrated to therapeutic
   dose (e.g., GPN, LEV) generally are better than
   drugs that require 6-12 weeks to achieve therapeutic
   dose (e.g., LTG).
2. The best dose is the lowest one that achieves
   complete seizure control without ARs  but allow
   margin of protection for lowering of seizure
   threshold (lack of sleep, intercurrent infection, etc.)
3. In general, the largest dose should be at bedtime,
   except if AED induces insomnia (e.g. LTG).
4. Allow patient to slow rate of AED titration if they
   wish, but not increase rate of titration (esp. LTG).
        Change timing of AED
           administration
Sometimes toxicity can be reduced or seizure
control improved simply by altering the timing
of AED dosing.
  Tmax = Time to peak concentration after drug
   administration
  For most IR drugs, the Tmax is 60-90 minutes
  If ARs occur 1-2 hours after oral administration,
   divide administration into smaller, more frequent
   doses.
  Caveat: adults have a difficult time with compliance if
   dosing > bid.
                   Compliance rates and
                   AED dosage regimen
                  100
                            87
          C                                81
          o                                         77
              R   80
          m
              a
          p
              t   60
          l
              e
          i                                                39
          a       40
          n
              %
          c       20
          e
                   0
                            QD            BID       TID    QID
                                          Dosing Regimen
Cramer et al., JAMA 1989; 261:3273-3277
        Half-lives of common AEDs
      1/2 day                ~1-2 days                       3-6 days
      carbamazepine           ethosuximide                    lamotrigine***
      gabapentin              felbamate                       phenobarbital
      lacosamide              lamotrigine**
      lamotrigine*            oxcarbazepine
      levetiracetam           (phenytoin)
      primidone               topiramate
      rufinamide              zonisamide
      tiagabine
      valproate
      vigabatrin
                              *as polytherapy with enzyme-inducing AEDs
                              **as monotherapy
                              ***as polytherapy with enzyme-inhibiting AEDs
Modified from Treiman, 1995
    Treatment administered by 12 physicians
         to King Charles II after a violent
               convulsion in 1685
 Bled one pint from right arm, 1/2 pint from right shoulder
 Emetic and two purgatives
 Enema containing 13 ingredients
 Sneezing powder to strengthen the brain
 Soothing drinks of barley water, licorice and almond,
  extract of mint, thistle leaves, rue and angelica
 Plaster of burgundy pitch and pigeon dung to chest
 As the king died, Raleighs antidote, pearl julep and
  ammonia was forced down his throat
         Drug interactions
Pharmacokinetic      Pharmacodynamic
Absorption               Efficacy
 Stability
      Complexation
       Dissolution
       Physiology
Distribution             Toxicity
 Binding
Elimination
 Metabolism
 Excretion
          Effects on AED elimination
                        Antiepileptic Drugs
                          Microsomal P450 enzyme:
       Inducers                Inhibitors           No effect
       CBZ                     FBM                  GPN
       PB                      VPA                  LCM
       PHT                     ZNS (min.PHT)        LTG
       PRIM                                         LEV
       OXC (estrogens, DHPs)                        PGB
       VGB                                          TIA
       ZNS (min.CBZ)                                TPM
Modified from Treiman, 1995
           Effects on AED elimination
                     Non-antiepileptic drugs
                                  Microsomal P450 enzyme:
     __Inducers___                _______Inhibitors________
     alcohol                  allopurinol          erythromycin
     nicotine                 chloramphenicol      isoniazid, PAS
     oral contraceptives      cimetidine           phenylbutazone
     other steroids           coumarin             propranolol
     phenothiazines           diltiazem,           propoxyphene
     rifampin                  other Ca blockers   sulfonamides
                              disulfiman
Modified from Treiman, 1995
                  Dont give up!
 Many AEDs abandoned before they have been pushed to
  maximum tolerated doses, because:
    titration too fast and thus avoidable ARs occur
    physician fearful of high doses/serum concentrations
 14 classical or new AEDs approved for partial onset szs
  and some primarily generalized szs (excluding niche
  AEDs). Thus there are 91 pairs and 364 triplets possible.
 Although probability of success decreases with number
  of combinations that fail, in the patient with uncontrolled
  seizures for whom surgical intervention is not a
  consideration, keep trying.
         Future developments
              in AED use
 Identification of new AEDs
 Development of true rational polypharmacy
 Development of strategies for improving AED
  efficacy in drug-resistant patients
 Development of antiepileptogenic strategies
 Personalized medicine: strategies to predict
   Which patients will develop ARs (e.g. HLA typing to
    predict Stevens-Johnson syndrome and toxic
    epidermal necrolysis)
   Which patients will respond to which AEDs.
  Impact on Clinical Care and Practice
To use AEDs in the most effective way possible:
 Treat the patient as an individual, based on data
 from population statistics.
 Get the diagnosis right, pick the right drug.
 Push the dose to full control but w/o ARs
 Know your drugs well (PKs, interactions, ARs)
 Keep trying  there are many possible
 combinations.